What progress has been made in treatment of immunocompromised COVID-19 patients?
Antiviral treatment
Covid 19
Glucocorticoids
Monoclonal antibodies
Journal
Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
pubmed:
16
9
2022
medline:
25
11
2022
entrez:
15
9
2022
Statut:
ppublish
Résumé
While immunocompromised patients are at very high risk of developing severe COVID 19, few of them have been enrolled in studies aimed at evaluating treatments. In the early stages of research on this disease, glucocorticoid therapy became the standard of care for patients requiring oxygen supplementation. It has been demonstrated that the neutralizing monoclonal antibody combination of Casirivimab and Imdevimab reduced (by 28 days) mortality in COVID-19 patients admitted to hospital who were seronegative at baseline, but not in those who were seropositive. There is still a need to determine the place of available various antivirals (Molnupiravir or Nirmatrelvir plus Ritonavir) and passive immunotherapies (Sotrovimab…) as well as convalescent plasma therapy in immunocompromised settings.
Identifiants
pubmed: 36108972
pii: S2666-9919(22)00191-9
doi: 10.1016/j.idnow.2022.09.009
pmc: PMC9468055
pii:
doi:
Substances chimiques
sotrovimab
1MTK0BPN8V
imdevimab
2Z3DQD2JHM
casirivimab
J0FI6WE1QN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S12-S15Informations de copyright
Copyright © 2022. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declaration of interest The authors declare no conflict of interest
Références
Leukemia. 2022 Apr;36(4):1025-1034
pubmed: 35105946
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet. 2022 Feb 12;399(10325):665-676
pubmed: 35151397
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
JAMA Netw Open. 2021 Nov 1;4(11):e2136030
pubmed: 34817587
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
JAMA. 2021 Nov 02;326(17):1690-1702
pubmed: 34606578
N Engl J Med. 2022 Mar 10;386(10):995-998
pubmed: 35081300